Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Policy / Regulatory

Jiangxi Healthcare Security Administration Launches New VBP Tender

Fineline Cube Nov 21, 2022

The Jiangxi Healthcare Security Administration (JHSA) has released a notice of a new volume-based procurement...

Company Deals

Fapon Biotech Partners with CR Pharma to Develop IVD Open Platform Ecosystem

Fineline Cube Nov 21, 2022

China-based biotech Fapon Biotech Inc. has announced a partnership with China Resources Pharmaceutical Commercial Group...

Company Drug

Henlius’ Serplulimab Phase III Study Approved in Spain for LS-SCLC

Fineline Cube Nov 21, 2022

China-based Shanghai Henlius Biotech (HKG: 2696) has announced that its global, multi-center Phase III clinical...

Company Drug

Hainan Poly Pharm Wins Finland Approval for Generic Cytovene-IV

Fineline Cube Nov 21, 2022

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...

Company Drug

Kangtai Biological Completes Phase III Clinical Data Analysis for COVID-19 Vaccine

Fineline Cube Nov 21, 2022

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the completion of the...

Policy / Regulatory

Jiangxi Leads 22-Province Alliance in VBP for Liver Function Test Reagents

Fineline Cube Nov 21, 2022

The provincial drug and medical consumables centralized procurement joint meeting office of Jiangxi has released...

Company Deals

Fapon Biotech Partners with Roche Diagnostics at China International Import Expo

Fineline Cube Nov 18, 2022

China-based biotech Fapon Biotech Inc. has announced a partnership with Swiss major Roche Diagnostics at...

Company Medical Device

China’s Jiangsu Bioda Gains NMPA Approval for Innovative Artificial Blood Vessel

Fineline Cube Nov 18, 2022

The National Medical Products Administration (NMPA) has granted marketing approval to China-based Jiangsu Bioda Life...

Company Drug

Visen Pharmaceuticals Publishes Phase III Data for Lonapegsomatropin in Growth Hormone Deficiency

Fineline Cube Nov 18, 2022

Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm...

Company Deals

RongCan Biotech Raises Pre-Series A Funding for mRNA Therapeutics Development

Fineline Cube Nov 18, 2022

China-based nucleic acid-based therapeutics developer RongCan (Shanghai) Biotech Co., Ltd has reportedly raised “tens of...

Company

Lee’s Pharmaceutical Reports Q3 2022 Financials with 8.8% Revenue Growth

Fineline Cube Nov 18, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its Q3 2022 financial report, recording...

Company Deals

Marinus Pharmaceuticals Collaborates with Tenacia Biotechnology for Ganaxolone

Fineline Cube Nov 18, 2022

Pennsylvania-based pharma company Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) has entered into a collaboration and supply...

Company Legal / IP

Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation

Fineline Cube Nov 18, 2022

US-based Mirati Therapeutics (Nasdaq: MRTX) is reportedly suing China-based InventisBio Co., Ltd (SHA: 688382) over...

Legal / IP Policy / Regulatory

CDE Issues Trial Rules for NMPA Drug Review Timekeeping Suspension

Fineline Cube Nov 18, 2022

The Center for Drug Evaluation (CDE) has released the “NMPA Drug Review Timekeeping Suspension and...

Company Medical Device

Bio-Heart Bio to Launch Clinical Study for Rapamycin Drug-Eluting Balloon in Japan

Fineline Cube Nov 18, 2022

China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that it will initiate...

Company Medical Device

Bio-Heart Bio Receives Ethical Approval for Iberis RDN System in Hainan

Fineline Cube Nov 18, 2022

China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced receiving ethical approval from...

Company Drug

BeiGene’s Brukinsa Receives EC Approval for CLL Treatment

Fineline Cube Nov 18, 2022

China-based biotech BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving marketing approval...

Company

Zhangjiang AI New Drug R&D Alliance Expands with New Members

Fineline Cube Nov 18, 2022

The Zhangjiang AI New Drug R&D Alliance has welcomed new participants, including Regor Therapeutics, Roche,...

Company Deals

Subtle Medical Secures Series B Funding for AI-Powered Medical Imaging

Fineline Cube Nov 17, 2022

Subtle Medical, an Artificial Intelligence (AI)-empowered medical imaging company based in Guangdong, has reportedly raised...

Company Drug

Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Three New Drugs

Fineline Cube Nov 17, 2022

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical trial approvals for three in-house...

Posts pagination

1 … 594 595 596 … 662

Recent updates

  • China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
  • Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
  • Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.